News|Videos|November 16, 2026

Remote Monitoring Strategies for CRS During Outpatient Bispecific Therapy

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

Ralph V. Boccia, MD, FACP, founder of The Center for Cancer and Blood Disorders, clinical associate professor at MedStar Georgetown University Hospital, and medical director of the International Oncology Network Clinical Research Program, detailed the tools and protocols his practice uses to monitor patients for adverse events, particularly cytokine release syndrome (CRS), during outpatient bispecific antibody therapy. Caregivers are equipped with a thermometer, a blood pressure cuff, and a pulse oximeter, and patients keep dexamethasone at home.

Boccia’s team uses prophylactic dexamethasone most of the time, as well as prophylactic tocilizumab (Actemra), especially for patients receiving bispecific antibodies for multiple myeloma. Patients are seen in the clinic the day after each step-up dose, followed by telehealth visits with an advanced practice provider (APP). He walked through a grade-based approach: managing grade 1 fever at home, escalating to in-office tocilizumab, steroids, fluids, and oxygen for persistent fever or grade 2 CRS, and admitting patients before they reach grade 3. He also described a wearable temperature patch and emerging services that offer remote monitoring by experienced nurses.

Transcript:

Boccia: The first thing we need to do is monitor the patient’s neurologic status and the potential for CRS. Monitoring a patient for CRS is pretty easy. At the very basic level, they have to have a thermometer, a sphygmomanometer to take their blood pressure, and an oxygen saturation device. Those are the 3 key things the caregiver needs to monitor the patient, and they record all those things. We also give them dexamethasone, so they have dexamethasone at home. If they develop a fever and it doesn’t seem like infection is what’s going on, they take their Tylenol and their dexamethasone, and then we monitor them over time. Sometimes we’re giving prophylactic dexamethasone, most of the time, and other times we’re also giving prophylactic tocilizumab, especially to our patients receiving bispecifics for multiple myeloma. That can go a long way toward blocking CRS, or at the very least limiting it to grade 1. That’s what we do for prophylaxis.

Then we see the patients in the clinic on the day after their step-up dose. Often, they come in and get some IV fluids; sometimes they get more steroids. They’re monitored for several hours, then sent home, and at the end of the day they get a telehealth visit, often with the APP, to go over how they did when they got home. On the third day, and often the fourth day, we’re often just doing 2 virtual visits. You can see the patient, look at the recordings the caregiver has made, and determine whether you need to see them face to face or, if worse comes to worst, meet them at the hospital. That’s how we manage and monitor.

If a patient develops grade 1 CRS, which is just a fever, a temperature of 100.4 °F or more, we’ll often try to manage that at home. If the fever doesn’t break in 24 hours, they come into the office, and we’ll often give them tocilizumab if they haven’t had it already. If we can’t break it, or if they have grade 2 CRS, meaning maybe they’re a little hypoxic or their blood pressure is a little soft and they still have the fever, then we’ll bring them into the office. We’ll often give them tocilizumab, we’ll always give them steroids, and we’ll give them IV fluids and monitor them with a little low-flow oxygen. Most of the time, by the end of the day, we’ve broken it. If we haven’t, they often go to the hospital, and that’s when we’ll admit them, because we don’t want them to be an outpatient with grade 3 CRS. That’s our outpatient strategy, and it’s worked well.

Right now, we also use a device that remotely monitors temperature. It’s a simple patch that goes on the arm, transmits to a monitor and then to a portal, and we can see it on the phone. Currently, that’s all we’re using because, as I said earlier, all CRS is heralded by a fever. That’s what you mostly need to know, because the caregiver can take the blood pressure and pulse and tell you. That said, we’re also now looking at companies that provide a more robust suite of services that can include all 3 of those measurements and have remote monitoring health care providers. They’re nurses who have worked with T-cell therapy themselves, who can take the calls and report back to the physicians if it’s anything other than something very simple. There are now services that basically have people on call to take those calls.



Related to this article